GlassScriptPhysician profile
Christopher M Bell
NPI 1225190382
$347,826.44
in general payments reported to CMS, 2019-2025
30 companies · $120K in 2025
The $120K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24K · 2022: $23K · 2023: $79K · 2024: $103K · 2025: $120K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Travel and Lodging: $56K · Consulting Fee: $28K · Food and Beverage: $15K · Honoraria: $1,500 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200,408.25 |
| Travel and Lodging | $56,130.21 |
| Consulting Fee | $28,327.00 |
| Food and Beverage | $14,950.18 |
| Honoraria | $1,500.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $131,885.36 | 2021-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $90,507.67 | 2021-2025 | Wainua, Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $37,081.86 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $25,974.44 | 2022-2025 | Ozempic, Wegovy |
| Scpharmaceuticals INC. | $20,510.22 | 2023-2024 | |
| Bridgebio Pharma, INC. | $12,294.49 | 2025 | Attruby |
| Akcea Therapeutics, INC. | $6,476.49 | 2021 | |
| Vifor Pharma, INC. | $5,217.59 | 2021-2022 | |
| Cvrx, INC. | $4,306.61 | 2024-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $4,163.11 | 2022-2023 | Optimizer |
| Boston Scientific Corporation | $2,292.01 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, General - Therapies |
| Medtronic, INC. | $1,994.41 | 2023-2024 | Symplicity G3, Reveal Linq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,299.51 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $997.52 | 2021-2025 | |
| Abbott Laboratories | $961.48 | 2021-2025 | Freestyle Libre Pro, Cardiomems, Mitraclip |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $400.97 | 2022-2025 | |
| Biotronik INC. | $369.43 | 2021-2022 | |
| Abiomed | $350.29 | 2023-2024 | Impella |
| Merck Sharp & Dohme LLC | $271.45 | 2021-2023 | Verquvo |
| Nuwellis, INC. | $93.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $63.30 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $55.01 | 2025 | |
| Amgen INC. | $54.88 | 2023-2025 | Repatha, Repatha |
| Daiichi Sankyo INC. | $52.53 | 2022-2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $50.38 | 2022-2023 | |
| Daxor Corporation | $41.15 | 2024 | Bva-100 |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Amarin Pharma, INC. | $19.10 | 2021 | |
| Sobi, INC | $16.44 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.06 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.